Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA?

19 set 2019 · FDA CDER Small Business and Industry Assistance (SBIA) Chronicles

00:07:49

Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA? | September 19, 2019 Issue

Ouvir Ouvir novamente Continuar A reproduzir…
Subscrever Cancelar subscrição
Partilhar

Episódios

Considerations for Drug Products that Contain Nanomaterials
15 mai· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Considerations for Drug Products that Contain Nanomaterials
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Using Bayesian statistical approaches to advance our ability to evaluate drug products
18 ago 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Using Bayesian statistical approaches to advance our ability to evaluate drug products
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Estão a faltar episódios?

Clique aqui para atualizar o feed.
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products
11 jul 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
10 abr 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
7 fev 2023· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
29 set 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
An FDA Self-Audit of Continuous Manufacturing for Drug Products
28 jun 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
The Key Elements of Being “Recall-Ready”
20 abr 2022· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
A voluntary recall is an action taken by a company to correct a violative product or remove it from the market.
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
The ABCs of Product Specific Guidances
3 set 2021· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Product-specific guidances (or PSGs for short) describe the Agency's current thinking on the evidence needed to demonstrate that a generic drug is therapeutically equivalent to the corresponding reference listed drug (RLD) product.
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Improving Regulatory Communication via the CDER NextGen Portal
19 dez 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA?
19 set 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Abbreviated Approval Pathways for Drug Product: 505(b)(2) or ANDA? | September 19, 2019 Issue
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Research Investigational New Drug Applications – What You Need To Know
25 jun 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
FDA recently released an update to clarify when ‘Research’ vs. ‘Commercial’ should be selected on FDA Form 1571, and thus when electronic common technical document or “eCTD” requirements would apply for an investigational new drug or “IND” application.
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
Competitive Generic Therapies
23 mai 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
Competitive Generic Therapies May 23, 2019 Issue
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois
FDA Modernizes Clinical Trials with Master Protocols
26 fev 2019· FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
"FDA Modernizes Clinical Trials with Master Protocols" February 26, 2019 Issue
- Ouvir Ouvir novamente Continuar A reproduzir…
- Ouvir depois Ouvir depois

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.